Collaboration between pharmaceutical industry and healthcare professionals (HCPs) and healthcare organisations (HCOs) benefits patients. It is a relationship that has delivered numerous innovative medicines and changed the way many diseases impact on our lives.
Furthermore, patient organisations (POs) play a critical role in Europe’s healthcare: from prevention and awareness, through research and development, regulatory and HTA decision making, to service design and outcomes measurement.
Bringing greater transparency to this already well-regulated and vital relationship, builds understanding of industry-POs and HCPs/HCOs collaboration and, in the context of increasing societal expectations on transparency, addresses directly public concerns about interactions between the medical community and the pharmaceutical industry.
That is why, on a voluntary basis, EFPIA has decided to disclose the amounts provided to POs, HCPs and HCOs:

EFPIA supported patient organisations and patient advocates to the value of €27,019.55 in 2017. This comprised of a €12,000 donations & grants to the European Patients Forum and €15,019.55 reimbursed to patient advocates for travel and accommodation for attending conferences and meetings across 2017.
EFPIA reimbursed Healthcare Professionals to the value of €1,551.76 for travel and accommodation for attending conferences and meetings across 2017.
EFPIA is committed to protecting and respecting the privacy of personal data. Individual persons have been informed of this data process, their right to correct the information and have provided consent for this disclosure.
Where applicable, the amounts disclosed do not include deductible VAT.